Syntara Interim Phase II Data SNT 5505,,,, SH Predictions......, page-26

This is the first of 4 Phase II candidates , 3 are in play currently .

SNT 6302 is being utilised by Prof Fiona Wood on Burns Grafts,

Parkinsons Trial underway in the UK

under its past incarnation PXS had invested over $120m on the 4 candidates gaining positive data from the previous phase I Trials...

just so you are aware SNT is not a 1 trick pony ,,, and when your SOI has 57% Biotech Fund and Insto ownership , my personal opinion is these organisations carry out really deep dive DD before tipping in millions...

Market can react in a million ways ,,,, but todays data is being presented to 30,000 global attendees, from a keynote mainstage presentation .... imagine the fund managers and Biotech Funds that will be present .... Best of luck with your investment here ,, I hope we kiss 10c today .... NZT